| Title |
An update on anticancer drug development and delivery targeting carbonic anhydrase IX / |
| Authors |
Kazokaitė, Justina ; Aspatwar, Ashok ; Parkkila, Seppo ; Matulis, Daumantas |
| DOI |
10.7717/peerj.4068 |
| Full Text |
|
| Is Part of |
PeerJ.. London : PeerJ Inc.. 2017, vol. 5, art. no. e4068, p. [1-31].. eISSN 2167-8359 |
| Keywords [eng] |
CA IX antitumor agents ; CA IX monoclonal antibodies ; carbonic anhydrase IX ; conjugated probes ; drug development ; hypoxic tumors |
| Abstract [eng] |
The expression of carbonic anhydrase (CA) IX is up-regulated in many types of solid tumors in humans under hypoxic and acidic microenvironment. Inhibition of CA IX enzymatic activity with selective inhibitors, antibodies or labeled probes has been shown to reverse the acidic environment of solid tumors and reduce the tumor growth establishing the significant role of CA IX in tumorigenesis. Thus, the development of potent antitumor drugs targeting CA IX with minimal toxic effects is important for the target-specific tumor therapy. Recently, several promising antitumor agents against CA IX have been developed to treat certain types of cancers in combination with radiation and chemotherapy. Here we review the inhibition of CA IX by small molecule compounds and monoclonal antibodies. The methods of enzymatic assays, biophysical methods, animal models including zebrafish and Xenopus oocytes, and techniques of diagnostic imaging to detect hypoxic tumors using CA IX-targeted conjugates are discussed with the aim to overview the recent progress related to novel therapeutic agents that target CA IX in hypoxic tumors. |
| Published |
London : PeerJ Inc |
| Type |
Journal article |
| Language |
English |
| Publication date |
2017 |
| CC license |
|
